SYNTHESIS AND TESTING OF NEW ANTIPROGESTATIONAL AGENTS
NIH GUIDE, Volume 23, Number 29, August 5, 1994
RFP AVAILABLE: NICHD-CD-94-13
P.T. 34
Keywords:
Chemical Synthesis
Chemistry, Organic
Contraceptives
National Institute of Child Health and Human Development
The Contraceptive Development Branch of the Center for Population
Research, National Institute for Child Health and Human Development
(NICHD) has a requirement for the synthesis and testing of
antiprogestational agents as postcoital antifertility agents. The
goals of this acquisition are to design, synthesize, and test
antiprogestational agents that are at least ten-fold more potent orally
than mifepristone in standard assays for antiprogestational activity in
laboratory animals. The selected prototypes for further structural
modification may be mifepristone or other leads that have demonstrated
oral activity. Such antagonists should, desirably, also have minimal
hormonal and other antihormonal activities for use as contraceptive
agents. Such antiprogestational agents must also be devoid of effects
on central nervous and cardiovascular systems. The Government will
carry out in vivo biological assays required to establish the
antiprogestational activity of compounds submitted to the Contraceptive
Development Branch under the auspices of this acquisition. Offerors
must undertake standard in vitro progesterone and glucocorticoid
binding assays on all the newly synthesized compounds in house or
through subcontracting. Specifically excluded from consideration are
(a) inhibitors of progesterone biosynthesis, and (b) estrogens.
Organizations must have adequate facilities and capabilities to carry
out the proposed synthetic chemical program and in vitro binding assays
as mentioned above. The Government estimates the effort to be
approximately 4.9 technical person-years annually. The principal
investigator must be a synthetic organic and/or medicinal chemist with
a Ph.D. degree, who will devote approximately 25 percent of her/his
time to the project and must have five years of experience in drug
synthesis. All responsible sources may submit a proposal that will be
considered by the agency. It is anticipated that four cost-
reimbursement incrementally funded type contracts will be awarded as a
result of the request for proposals (RFP) for a period of 36 months,
beginning June 1, 1995. This announcement is not an RFP. RFP
NICHD-CD-94-13 will be available on or about August 19, 1994.
Proposals will be due approximately 120 days thereafter.
INQUIRIES
Requests for copies of the RFP must cite the RFP number and be
addressed to:
Paul J. Duska
Office of Grants and Contracts
National Institute of Child Health and Human Development
6100 Building, Room 7A07
Bethesda, MD 20892
FAX: (301) 402-3676
.